27 related articles for article (PubMed ID: 35436669)
1. Highly Potent Non-Carboxylic Acid Autotaxin Inhibitors Reduce Melanoma Metastasis and Chemotherapeutic Resistance of Breast Cancer Stem Cells.
Banerjee S; Norman DD; Lee SC; Parrill AL; Pham TC; Baker DL; Tigyi GJ; Miller DD
J Med Chem; 2017 Feb; 60(4):1309-1324. PubMed ID: 28112925
[TBL] [Abstract][Full Text] [Related]
2. Designing Dual Inhibitors of Autotaxin-LPAR GPCR Axis.
Banerjee S; Lee S; Norman DD; Tigyi GJ
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080255
[TBL] [Abstract][Full Text] [Related]
3. Novel imidazo[1,2-a]pyridine derivatives as potent ATX allosteric inhibitors: Design, synthesis and promising in vivo anti-fibrotic efficacy in mice lung model.
Lei H; Li Z; Li T; Wu H; Yang J; Yang X; Yang Y; Jiang N; Zhai X
Bioorg Chem; 2022 Mar; 120():105590. PubMed ID: 34998121
[TBL] [Abstract][Full Text] [Related]
4. Hybrid imidazo[1,2-a]pyridine analogs as potent ATX inhibitors with concrete in vivo antifibrosis effect.
Li T; Lei H; Yang J; Cao Z; Yang Y; Liu Z; Sun R; Yang X; Zhai X
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200171. PubMed ID: 35661405
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and anti-fibrosis evaluation of imidazo[1,2-a]pyridine derivatives as potent ATX inhibitors.
Chen Y; Lei H; Li T; Cui Y; Wang X; Cao Z; Wu H; Zhai X
Bioorg Med Chem; 2021 Sep; 46():116362. PubMed ID: 34428714
[TBL] [Abstract][Full Text] [Related]
6. Discovery and optimization of tetrahydropyrido[4,3-d]pyrimidine derivatives as novel ATX and EGFR dual inhibitors.
Jing T; Miao X; Jiang F; Guo M; Xing L; Zhang J; Zuo D; Lei H; Zhai X
Bioorg Med Chem; 2018 May; 26(8):1784-1796. PubMed ID: 29496411
[TBL] [Abstract][Full Text] [Related]
7. Structural and PK-guided identification of indole-based non-acidic autotaxin (ATX) inhibitors exhibiting high in vivo anti-fibrosis efficacy in rodent model.
Lei H; Cao Z; Wu H; Li T; Wang X; Chen Y; Ma E; Sun L; Zhai X
Eur J Med Chem; 2022 Jan; 227():113951. PubMed ID: 34742015
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and promising anti-tumor efficacy of novel imidazo[1,2-a]pyridine derivatives as potent autotaxin allosteric inhibitors.
Lei H; Wang X; Zhao G; Li T; Cui Y; Wu H; Yang J; Jiang N; Zhai X
Eur J Med Chem; 2022 Jun; 236():114307. PubMed ID: 35436669
[TBL] [Abstract][Full Text] [Related]
9. An updated patent review of autotaxin inhibitors (2017-present).
Tan Z; Lei H; Guo M; Chen Y; Zhai X
Expert Opin Ther Pat; 2021 May; 31(5):421-434. PubMed ID: 33342311
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin inhibitors: a patent review (2012-2016).
Nikolaou A; Kokotou MG; Limnios D; Psarra A; Kokotos G
Expert Opin Ther Pat; 2017 Jul; 27(7):815-829. PubMed ID: 28447479
[TBL] [Abstract][Full Text] [Related]
11. Autotaxin inhibitors: a patent review.
Barbayianni E; Magrioti V; Moutevelis-Minakakis P; Kokotos G
Expert Opin Ther Pat; 2013 Sep; 23(9):1123-32. PubMed ID: 23641951
[TBL] [Abstract][Full Text] [Related]
12. Computer Aided Drug Design Approaches for Identification of Novel Autotaxin (ATX) Inhibitors.
Vrontaki E; Melagraki G; Kaffe E; Mavromoustakos T; Kokotos G; Aidinis V; Afantitis A
Curr Med Chem; 2016; 23(17):1708-24. PubMed ID: 26997151
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]